IngredientsPhosphatidylethanolamine (commonly abbreviated PE) is a major class of glycerophospholipid found in virtually all living organisms. Its historical synonym is cephalin (from the Greek kephalē, meaning "head" or "pertaining to the head"), reflecting its original isolation from brain tissue. Phosphatidylethanolamine is infrequently referred to as cephalin, from the word cephalic meaning "pertaining to the head," and is the second most prevalent phospholipid in humans but is the principal phospholipid in bacteria. The IUPAC systematic designation describes the molecule as a 1,2-diacyl-sn-glycero-3-phosphoethanolamine, though the exact species name varies according to the identity of the attached fatty acid chains.
PE is composed of a glycerol backbone, two fatty acid chains, a phosphate group, and an ethanolamine molecule; this architecture is a testament to its vital role in maintaining cell integrity. Specifically, PE harbors two fatty acid chains that extend from the glycerol backbone, which, being typically composed of hydrophobic tails, contribute to the amphipathic nature of phospholipids, enabling them to form the lipid bilayer — a fundamental structure of cell membranes. Distinctive to phosphatidylethanolamine, the ethanolamine molecule is linked to the phosphate group; this hydrophilic component further enhances the amphipathic nature of PE, contributing to its dynamic interactions within the lipid bilayer.
An important structural feature distinguishing PE from phosphatidylcholine (PC) is its molecular geometry. PE is a non-bilayer-forming phospholipid containing a small polar head group diameter in proportion to its fatty acid chains. The intrinsic biophysical properties of this cone-shaped lipid induce the formation of hexagonal phases within the membrane and, in so doing, promote membrane fusion and fission events, protein integration into membranes, and conformational changes in protein structure. The fatty acid residues esterified at the sn-1 and sn-2 positions of the glycerol backbone may include palmitic, stearic, oleic, linoleic, linolenic, arachidonic, and docosahexaenoic (DHA) acyl chains, giving rise to a diverse family of molecular species. The fatty acid substituents can range from straight or branched carbon acyl radicals ranging from 2 to 24 carbon atoms, or the corresponding acyl radicals of unsaturated fatty acids, such as oleic, stearic, linoleic, linolenic, palmitic, myristic, or arachidonic acids.
Two prominent forms recognized in commerce and research are diacyl-PE (the predominant naturally occurring form) and plasmalogen-PE (also called ethanolamine plasmalogen), in which the sn-1 position carries a vinyl ether rather than an ester linkage. Both forms are biologically and nutritionally relevant, though plasmalogen-PE is particularly enriched in neural tissue and cardiac muscle.
Phosphatidylethanolamine is produced naturally in virtually all living cells, where it serves as a foundational phospholipid supporting membrane structure, cellular energy, and metabolic regulation. PE is the second most abundant phospholipid in the cell, comprising 15–25% of total phospholipids in mammalian cells.
Animal sources: In humans, PE is found particularly in nervous tissue including the white matter of the brain, nerves, and in the spinal cord. PE, PC, and cholesterol are also major components of egg yolk, a ready and inexpensive source of these lipids. PE is predominantly found in foods such as soybeans and egg yolks, accounting for 15–25% of the total phospholipid in mammalian cells, and is the second most abundant phospholipid.
Plant sources: Phosphatidylethanolamine is also found abundantly in soy or egg lecithin and is produced commercially using chromatographic separation. Soy lecithin granules contain approximately 42% phosphatidylcholine, 36% PE, and 22% phosphatidylinositol. Other plant-based sources include wheat, nuts, flaxseeds, sunflower seeds, and a variety of legumes. Phospholipids are present in various foods, such as milk, chicken eggs, soy, fish eggs, and sunflower seeds.
Microbial/bacterial sources: Phosphatidylethanolamine is a major lipid component of cellular membranes in a wide range of organisms. In Escherichia coli, PE accounts for 70–80% of total membrane lipids. This prominence in bacterial membranes has made PE an important subject of antimicrobial research.
Commercial production: PE is extracted industrially from soy lecithin and egg lecithin using chromatographic techniques. In addition to endogenous synthesis, PE is present in a variety of dietary and botanical sources, making it relevant for nutrition, supplements, and industrial extraction.
The scientific history of PE dates to the mid-nineteenth century. In 1846, Gobley reported that egg yolk contained a phosphorus-containing lipid that he called "lecithin," derived from the Greek word for egg yolk. Later, Diakonow concluded that choline and fatty acids were also components of the lecithin molecule. Remarkably, as early as 1874, Johann Ludwig Wilhelm Thudichum showed that the products of the complete hydrolysis of lecithin were phosphoric acid, glycerol, fatty acids, and an organic base that contained a nitrogen atom. He coined the term "phosphatides" for this class of molecules (now known as the phosphoglycerolipids).
In further studies reported in 1884, Thudichum separated two types of phosphatides from the brain on the basis of their solubility in alcohol: lecithin (now known as PC), which readily dissolved in alcohol, and "cephalin," which was not soluble in alcohol. He suggested that instead of the choline constituent that was present in lecithin, cephalin contained an alternative nitrogenous base, originally called colamine (now known as ethanolamine). Thudichum (1829–1901) was a German biochemist and physician who in 1884 published a book entitled "A Treatise on the Chemical Constitution of the Brain." At the time of its publication, this book was widely criticized by many in the scientific community.
PE was first purified more than one hundred years ago (1913) from cattle brain by Renall, who discovered that the two acyl chains of PE were typically different from one another, as was also the case for lecithin. The complete chemical synthesis of distearoyl-PE was subsequently achieved in 1924 by Levene and Rolf, providing definitive confirmation of the molecule's structural makeup. As a sequel to Thudichum's work, Taurog, Entemann, and Chaikoff showed that lecithin and cephalin were widely distributed in animal tissues such as the liver, heart, and brain. They also found that the phospholipids in plasma from humans and dogs consisted almost entirely of the choline-containing phospholipids, with only 5% of total plasma phospholipids being cephalin. These observations, made in 1944, are entirely consistent with today's knowledge of plasma lipids.
Later in the twentieth century, Jordi Folch-Pi further elucidated the structure of "cephalin," demonstrating that the fraction isolated by Thudichum was in fact a mixture of lipids. Folch-Pi discovered that cephalin, long thought to be an ethanolamine-containing phospholipid, was actually a mixture of lipids, one of which was inositol. This laid the groundwork for modern phospholipid biochemistry and the recognition of PE as a distinct, ubiquitous molecular entity.
Because PE is an endogenous and dietary molecule — rather than a traditional botanical remedy — there is no documented history of its deliberate use in pre-modern herbal or folk medicine. Its entire history of use is scientific and technological, beginning in the late nineteenth century. The use of lecithin-rich preparations (from egg yolk and soybeans) in foods and early pharmacopoeia formulations did, however, deliver PE as an incidental constituent, even if it was not recognized as a distinct compound at the time.
PE is made in mammalian cells by two completely independent major pathways. In one pathway, phosphatidylserine (PS) is converted into PE by the mitochondrial enzyme PS decarboxylase. In addition, PE is made via the CDP-ethanolamine pathway, in which the final reaction occurs on the endoplasmic reticulum and nuclear envelope. Elimination of either pathway is embryonically lethal, despite the normal activity of the other pathway. This extraordinary observation establishes that each biosynthetic route contributes non-redundant, indispensable functions.
In mammals, PE is a substrate for methylation to PC in the liver, a substrate for anandamide synthesis, and supplies ethanolamine for glycosylphosphatidylinositol anchors of cell-surface signaling proteins. The conversion of PE to PC in the liver is catalyzed by the enzyme phosphatidylethanolamine N-methyltransferase (PEMT). The biosynthesis of PC from PE in mammals is catalyzed by PEMT via three sequential steps of PE methylation by transferring the methyl group from S-adenosylmethionine to the corresponding substrates; this process mediates about 30% of liver PC biosynthesis and is one of three PC biosynthesis pathways in mammalian cells.
PS is made in ER membranes and is imported into mitochondria for decarboxylation to PE via a domain of the ER known as mitochondria-associated membranes (MAM). Elimination of PS decarboxylase in mice caused mitochondrial defects and embryonic lethality. The tight regulation of PE levels across compartments underscores its importance not merely as a structural building block but as a metabolically active signal molecule.
PE influences everything from cell structure and mitochondrial function to nutrient absorption and intracellular signaling. The cone-shaped geometry of PE — arising from the relatively small ethanolamine head group relative to the bulky acyl tails — is critical to membrane curvature. The molecular structure of PE exhibits an inverted cone shape with a net neutral head group, in contrast to the cylindrical shape of phosphatidylserine with its net negatively charged head group. This geometric property directly drives membrane fusion, vesicle formation, and the topological organization of membrane proteins.
The fatty acid chains in PE, with their varying degrees of saturation, impact the fluidity of the cell membrane. Because of its unique physical properties, PE is at the hub of numerous cellular processes.
Mitochondrial function is severely impaired when the PE content of mitochondria is reduced below a threshold level. PE is the predominant phospholipid of the inner mitochondrial membrane, where it supports the electron transport chain, membrane potential maintenance, and oxidative phosphorylation. The content of PE affects oxidative phosphorylation and mitochondrial function, which is implicated in cardiovascular diseases. The essential role of mitochondria-localized PE synthesis is confirmed by the embryonic lethality seen when the mitochondrial PS decarboxylase pathway is abolished.
PE plays an obligatory, enzymatic role in the execution of autophagy — the cellular "self-eating" process essential for quality control and survival under stress. In particular, PE is the anchor for the microtubule-associated protein 1A/1B-light chain 3 (LC3), which is necessary for the formation of the autophagosome. PE becomes conjugated to cytosolic LC3-I to form membrane-bound LC3-II, which initiates autophagosome elongation. More precisely, LC3-I is conjugated with phosphatidylethanolamine via the actions of Atg3 and Atg7 to produce LC3-II, which integrates into both the inner and outer membranes of the autophagosome, allowing it to bind and sequester cargo for degradation; maturation then occurs as the autophagosome fuses with lysosomes, resulting in the degradation of engulfed organelles and proteins. This indicates that PE, through its interactions with the Atg8 proteins, is critical for both autophagy and mitophagy.
PE is a central executioner of ferroptosis, a form of iron-dependent regulated cell death characterized by lipid peroxidation. Ferroptosis is a regulated iron-dependent cell death mechanism accompanied by the accumulation of peroxidized phospholipids, particularly phosphatidylethanolamine, in the cell. It occurs due to the disbalance between production and elimination of oxidized phospholipids in response to ferroptotic stimuli. Specifically, arachidonoyl-PE and adrenoyl-PE species are the primary peroxidation targets. The dual nature of PE in cell death pathways — it is required for survival-linked autophagy yet drives ferroptotic death when peroxidized — makes the regulation of PE composition a critical cellular balancing act.
PE is asymmetrically distributed in the plasma membrane under normal conditions, concentrated in the inner (cytoplasmic) leaflet. During cell division, PE transiently appears on the outer leaflet at the cleavage furrow, where it is required for the contractile ring to function properly and for successful cytokinesis. This transient externalization is regulated and essential; perturbation of PE asymmetry can disrupt mitotic fidelity.
In mammals, PE is a substrate for anandamide synthesis, and it supplies ethanolamine for glycosylphosphatidylinositol (GPI) anchors of cell-surface signaling proteins. Anandamide (N-arachidonoylethanolamine) is an endogenous cannabinoid neurotransmitter derived partly through PE-mediated pathways, linking PE directly to endocannabinoid signaling relevant to pain, mood, and appetite regulation.
PE exposed on the outer leaflet of apoptotic and bacterial membranes serves as a recognition signal (a "find-me/eat-me" signal) for phagocytes. For bacteria, which contain PE but largely lack PS in their membranes, PE engagement enables the binding and uptake of spheroplasts and bacterial extracellular vesicles that are unsheathed by the cell wall. The direct recognition of PE facilitates mechanisms of clearance that stand to have a broad impact on the immune response.
PE is a vital part of the red blood cell membrane and is one of the most prevalent phospholipids in the human brain. It plays a crucial role in supporting the healthy physical and mental development of infants and young children. Additionally, it is closely associated with the prevention and slowing of the progression of neurodegenerative diseases, including Parkinson's and Alzheimer's diseases.
Phosphatidylethanolamine is known for playing a significant role in cellular membrane formation, cognition, and memory. A 2026 review published in the Journal of Nutrition specifically examined PE's role in neurological disease. From a biological perspective, PE is involved in constructing membranes and plays a crucial part in mitochondrial biogenesis, ferroptosis, cell autophagy, cell division, synthesis of biomolecules, and other processes.
A 2025 PubMed review focused on disturbances in mitochondrial function and phosphatidylethanolamine metabolism, noting that the resulting neuronal dysfunction is a common feature of individuals suffering from neurodegenerative diseases, highlighting the great importance of maintaining proper phosphatidylethanolamine homeostasis in neurons. The review summarized current knowledge of PE metabolism and its role in neuronal function with a special emphasis on the PE biosynthetic pathway in mitochondria, and reviewed findings on how PE biosynthesis is affected in major neurodegenerative diseases.
Alzheimer's disease (AD): Post-mortem and lipidomic studies have consistently found alterations in PE species in the brains of AD patients. Plasmalogen-PE (PL) is emerging as both a diagnostic and therapeutic target for neuropathological decline and dementia. Brain PL levels are lower in AD than in age-matched controls, and low brain levels correlate with low serum levels. A large post-mortem study examining 100 elderly subjects from the Rush University Memory and Aging Project measured specific PE and plasmalogen-PE species in the inferior temporal cortex alongside amyloid plaque and neurofibrillary tangle densities. The study has several limitations: it was designed to focus on a single class of lipids in a single brain region to investigate specific membrane structural changes with pathology and cognition; extrapolation of the results to other lipid classes, brain regions, or other pathologies was not investigated. No interventional human clinical trial has yet demonstrated that oral PE supplementation reverses or halts AD progression.
Parkinson's disease (PD): Normal levels of PE can decline with age in the brain. Yeast and worm models were used to test the hypothesis that low levels of PE alter the homeostasis of the Parkinson disease-associated protein α-synuclein (α-syn). In yeast, low levels of PE in the phosphatidylserine decarboxylase deletion mutant cause decreased respiration, endoplasmic reticulum (ER) stress, a defect in the trafficking of the uracil permease, α-synuclein accumulation and foci, and a slow growth phenotype. Preclinical studies in invertebrate models have shown that ethanolamine supplementation — which raises PE levels — can rescue α-synuclein-induced neurodegeneration. Ethanolamine supplementation over several days rescued neurodegeneration in α-synuclein/psd-1 worms. Strikingly, it also rescued age-dependent neurodegeneration in α-synuclein/EV control worms, which was unexpected because such worms should have normal levels of PE. Collectively, ethanolamine rescues α-synuclein-induced neurodegeneration with or without the depletion of psd-1. These findings are preclinical and have not been replicated in human trials.
Evidence strength assessment: Current evidence for PE in neurological disease is largely mechanistic, epidemiological (lipidomic associations), and from preclinical models (yeast, worms, mice). Direct human clinical trials testing PE supplementation for cognitive outcomes are limited and have typically used phospholipid mixtures (e.g., soy lecithin containing PE, PC, and other phospholipids) rather than isolated PE. Human data directly testing phosphatidylethanolamine supplementation are limited and often indirect: some small studies using ethanolamine-based plasmalogens or phospholipid mixtures suggest potential benefits for cognitive function or metabolic markers, but sample sizes are small and formulations vary.
The ratio of PC to PE in hepatocytes is a key regulator of liver membrane integrity and fat metabolism, with important implications for non-alcoholic fatty liver disease (NAFLD). Nonalcoholic fatty liver disease is associated with altered hepatic lipid composition. Animal studies suggest that the hepatic ratio of phosphatidylcholine to phosphatidylethanolamine contributes to steatogenesis and inflammation. This ratio may be influenced by dysregulation of the PE N-methyltransferase (PEMT) pathway or by a low-choline diet.
A human study involving 203 obese subjects undergoing bariatric surgery found significant associations between serum PE profiles and the histological spectrum of NAFLD. Previous studies have collectively demonstrated the association between perturbation in PE levels and NAFLD, with a decreased PC/PE ratio associated with both liver steatosis and NASH, while increased level of PE was specifically associated with NASH and disease progression. This is, at least in part, attributed to the insufficiency of phosphatidylethanolamine N-methyltransferase (PEMT), a key enzyme converting PE to PC.
A separate clinical study of NAFLD patients found that NAFLD patients have a lower PC/PE ratio in the liver and erythrocytes than do healthy controls, which may play a role in the pathogenesis. Genetic studies have identified polymorphisms in the PEMT gene as a susceptibility factor for NAFLD, underscoring the central importance of PE-to-PC conversion in liver homeostasis. PEMT mRNA expression in liver tissues of NASH patients was significantly lower than those with simple steatosis.
Evidence strength assessment: The association between altered PC/PE ratios and NAFLD/NASH is supported by multiple human cross-sectional and cohort studies, as well as genetic data. However, these findings implicate a dysregulation of PE metabolism rather than establishing benefit from PE supplementation. No large-scale, randomized, placebo-controlled trial of isolated PE supplementation for liver disease in humans has been published.
In a prospective population-based Bruneck Study, a survey of atherosclerosis and cardiovascular diseases conducted in 2000, PE was demonstrated to be associated with cardiovascular diseases, with PE (36:5) possessing the strongest predictive value. This epidemiological finding associates specific PE species with cardiovascular risk, though causation has not been established. The content of PE affects oxidative phosphorylation and mitochondrial function, which is implicated in cardiovascular diseases.
Evidence strength assessment: The cardiovascular associations with specific PE species come primarily from observational/epidemiological lipidomics studies. No interventional human clinical trials of isolated PE supplementation for cardiovascular endpoints have been identified in the peer-reviewed literature. The relationship is complex: different PE species (saturated vs. polyunsaturated acyl chains) may have divergent effects on cardiovascular biology.
Recent genetic discoveries have established that disruptions to PE biosynthetic pathways cause severe human neurological diseases. Multiple genetic disorders that impact PE biosynthetic pathways have been identified, including hereditary spastic paraplegia types 81 and 82, Liberfarb syndrome, and a new type of childhood-onset neurodegeneration (CONATOC). Individuals with these diseases suffer from multisystem disorders mainly affecting neuronal function. This indicates the importance of maintaining proper phospholipid homeostasis when major biosynthetic pathways are impaired. These monogenic disorders provide the clearest human evidence that PE is indispensable for neuronal health.
PE has been reported to associate with various cell functions including programmed cell death (PCD), autophagy, and mitochondrial fusion. In cancer biology, PE is both a substrate for the autophagy machinery (which may suppress or support tumor growth depending on context) and the primary peroxidation target during ferroptosis, a mechanism being actively explored as a cancer therapy. Recent studies on lipid-induced ER stress and ferroptosis show an intricate balance between saturated and unsaturated lipids in the membranes of the ER. Disruption of this balance can be devastating to cells. An excess of saturated lipids in the ER membranes decreases membrane fluidity and triggers ER stress; on the other hand, an excess of PE species with polyunsaturated acyl chains in the ER membranes can, if there are any perturbations of redox buffering, trigger the formation of toxic PE hydroperoxides that kill cells. Current evidence in this area is preclinical; no clinical trial of PE manipulation for oncological purposes has been identified.
PE is available as a dietary supplement primarily in the following forms:
Phosphatidylethanolamine (PE) is an important nutrient that is present in most foods, including eggs, wheat, nuts, and flaxseeds. Because PE is a dietary constituent rather than a classical pharmacological agent, most regulatory frameworks treat it as a food component.
Specific dosages for isolated PE supplementation in human clinical trials have not been widely published in peer-reviewed literature. Most human phospholipid studies have used mixed phospholipid preparations. As one example, phosphatidylserine (a related aminophospholipid frequently studied alongside PE) has been examined at doses such as 600 mg/day in a 6-month randomized controlled trial context, but this reflects PS rather than PE specifically. The absence of established clinical dosages for isolated PE reflects the relative paucity of dedicated human PE supplementation trials.
PE comprises approximately 15–25% of the total lipid content of the cell membrane and is an important nutrient that is present in most foods, including eggs, wheat, nuts, and flaxseeds. Its near-universal presence in the human diet and in every cell of the body suggests a wide margin of safety under normal dietary conditions.
According to safety data, concentrated, pure phosphoethanolamine (the head group component) can damage the skin and eyes when applied topically. Intravenous (IV) administration of a high dose of pure phosphoethanolamine can be harmful, according to animal studies. These concerns relate to the isolated precursor compound rather than the intact PE phospholipid as consumed in foods or supplements.
Pre-clinical toxicology studies of phosphoethanolamine administered orally to animals have found it to be generally safe. On the maximum dosage tolerated test, all dosages tested were safe and the animals showed no weight or nourish pattern alteration; in addition, no significant hematological and biochemical alteration were noted. In vitro genotoxicity evaluated with Salmonella typhimurium showed a mutagenic index of less than 2 (not mutagenic); micronucleus genotoxicity tests in accordance with OECD 471 guidelines did not observe genotoxicity at 8, 50, 320, and 2,000 mg/kg dosage; the in vivo evaluation of cardio and neurotoxicity of orally supplemented phosphoethanolamine showed neurologic and cardiologic safety.
Theoretical concerns at high doses: There are theoretical concerns that high-dose PE supplementation could interfere with fine-tuned autophagy signaling, which can be harmful if over-activated or suppressed inappropriately, and could influence progression of existing cancers, positively or negatively, because autophagy and membrane dynamics are involved in tumor biology. These concerns come mainly from mechanistic reasoning and preclinical research rather than clinical studies. The absence of clear danger in humans does not equal proof of safety, especially for high-dose, long-term use.
Ferroptosis and oxidative balance: PE species enriched in polyunsaturated fatty acids (PUFA-PE) can be oxidized to form hydroperoxyl intermediates that drive ferroptotic cell death. While this is the normal function of such species in specific contexts (e.g., tumor suppression), extreme supplementation with PUFA-rich PE in the context of impaired antioxidant defenses could, in theory, increase oxidative burden in sensitive tissues.
PEMT pathway and methyl donor status: The conversion of PE to PC via PEMT consumes S-adenosylmethionine (SAM), a universal methyl donor. In individuals with deficient methyl donor status (low folate, B12, or choline intake), extremely high PE intake might theoretically amplify demand on the methylation pathway; however, no clinical data directly documenting this interaction have been identified.
Drug interactions: At a cellular level, both PE and PC serve as substrates for MDR1 P-glycoprotein, the multidrug resistance transporter. The multidrug resistant cell line CEM/VBL300 and the parental CEM T-lymphoblastic cell line were used to study the accumulation of fluorescent phospholipid analogs of phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine (PS). Whether this interaction has clinical significance for individuals taking P-glycoprotein substrates (certain chemotherapeutic, immunosuppressive, or cardiac drugs) at pharmacological doses of PE is not established in human data.
Soy allergy: Individuals with soy allergy should be aware that most commercially available PE supplements are soy-derived. While the phospholipid fraction is largely devoid of soy proteins, highly sensitive individuals may wish to use egg-derived or sunflower-derived preparations.
As of 2026, the scientific literature on PE is expansive at the biochemical, cellular, and preclinical levels. The role of PE in membrane structure, mitochondrial function, autophagy, ferroptosis, and neurodegeneration pathways is well-established through molecular biology, genetics, and animal models. Human observational and lipidomic studies support associations between PE metabolism and diseases including NAFLD, Alzheimer's disease, Parkinson's disease, and cardiovascular disease.
However, rigorous, adequately powered, randomized placebo-controlled clinical trials specifically testing isolated PE supplementation in humans for any of these conditions are largely lacking as of the time of writing. Most human evidence comes from studies of mixed phospholipid products, surrogate biomarker endpoints, or post-mortem tissue analyses. The translation of compelling mechanistic and epidemiological findings into evidence-based supplementation recommendations awaits dedicated clinical investigation.
Health conditions that Phosphatidylethanolamine may help support.
Phosphatidylethanolamine (PE) is the second most abundant phospholipid in neuronal membranes, critical for maintaining membrane curvature, synaptic vesicle fusion, and mitochondrial function in neurons. It is essential for proper nervous system structural integrity and function.
Body systems that Phosphatidylethanolamine may help support.
Go back